Publication:
Economic burden of multidrug-resistant tuberculosis: a multicenter study across Vietnamese regions

dc.contributor.authorV. X. Namen_US
dc.contributor.authorN. V. Nhungen_US
dc.contributor.authorN. B. Hoaen_US
dc.contributor.authorH. T.T. Thuyen_US
dc.contributor.authorN. T.M. Phuongen_US
dc.contributor.authorN. T. Anhen_US
dc.contributor.authorL. T. Ngoc Anhen_US
dc.contributor.authorV. Q. Trungen_US
dc.contributor.authorT. V. Haen_US
dc.contributor.authorA. Meeyaien_US
dc.contributor.authorM. Thavorncharoensapen_US
dc.contributor.authorU. Chaikledkaewen_US
dc.contributor.otherMinistry of Health Vitenamen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherViet Namese National Tuberculosis Programen_US
dc.contributor.otherUniversity of Medicine and Pharmacyen_US
dc.date.accessioned2019-08-23T11:51:21Z
dc.date.available2019-08-23T11:51:21Z
dc.date.issued2018-08-01en_US
dc.description.abstract© 2018 The Union. S E T T I N G: Multidrug-resistant tuberculosis (MDR-TB) has become a major worldwide health problem. Various studies have been conducted on the cost of MDR-TB treatment; however, this has remained largely unexplored in Viet Nam. O B J E C T I V E: To estimate the total cost of MDR-TB treatment at several health care facilities in Viet Nam. D E S I G N: A prospective, prevalence-based study was conducted at three selected centers from March to June 2016 in 204 patients, 102 of whom were treated for 9 months and 102 for 20 months. Direct medical costs were calculated using electronic hospital databases, while a questionnaire was used to interview participants for evaluating direct non-medical and indirect costs. Total costs were estimated from a societal perspective in 2017 USD. R E S U L T S: Patients were mostly males aged 25–44 years. The average length of hospitalization in the 9-month treatment group was 168 6 127 days; in the 20-month group, it was 671 6 119 days. The average treatment cost for MDR-TB was respectively US$1480.34 6 211.61 and US$2695.58 6 294.98 for the 9- and 20-month treatment groups. Direct medical costs generally accounted for the highest proportion of the total costs, while the cost of pharmaceuticals and materials comprised the highest direct cost. C O N C L U S I O N: There was a significant difference in total costs among the three hospitals in the 9- and 20-month treatment groups.en_US
dc.identifier.citationInternational Journal of Tuberculosis and Lung Disease. Vol.22, No.8 (2018), 912-917en_US
dc.identifier.doi10.5588/ijtld.18.0039en_US
dc.identifier.issn18157920en_US
dc.identifier.issn10273719en_US
dc.identifier.other2-s2.0-85049753635en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/46470
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85049753635&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleEconomic burden of multidrug-resistant tuberculosis: a multicenter study across Vietnamese regionsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85049753635&origin=inwarden_US

Files

Collections